All News
Sex related differences in PsA
Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA).
Read Article
For daily recaps, content and updates from #ACR24 head to https://t.co/eL0bMhnFiu @RheumNow with input from colleagues in the faculty
@synovialjoints
@bella_mehta
@ericdeinmd
@AkhilSoodMD.
@DrMiniDey
@CaoilfhionnMD
@ebrhuem
@rheumarampa
@Dr_Brian_MD
@AdelaCastro222
@JihaRheum… https://t.co/a3FQjGokhn https://t.co/1g3Fi01HWG
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#Ianalumab
300 mg sc q monthly
B cell depleted and changes BAFF signalling
👇⬇️IFN
May be promising in #lupus #SLE
+data in primary #Sjogrens
ACR24 @RheumNow @ACRheum
Abst#2425
Needs Phase3
➡️I suspect safer than CAR T and Bispecific T cell engagers but
? ⬇️efficacy
Janet Pope Janetbirdope ( View Tweet)
ACR24 take homes
➡️#Inflammatory #myositis
#Upadacitinib improved MDA5 ILD
#Baricitinib 4mg/d good in myositis delayed start #RCT
#Tofacitinb ➡️help for skin, calcinosis, rash in case series
➡️RCT ongoing
JAKi is ‘jacked’ in muscles 💪🏿
#ACR24 @RheumNow @ACRheum
1731 0348
Janet Pope Janetbirdope ( View Tweet)
Biggest absence award at #ACR24 @ACRheum @RheumNow
🥇
Absence of discussion on
👇
#Oral #Surveillance
Except for maybe
Monitoring for mouth ulcers and cancers
issues are not resolved but we are comfortable with ambiguity!
Janet Pope Janetbirdope ( View Tweet)
Taking CAR-T for a Test Drive
What is CAR-T? How can you get a healthy dose of it at #ACR24? And what does it mean for the future? Read on to find out!
https://t.co/TnNHzWQndp https://t.co/qWgwjiEdLF
Dr. John Cush RheumNow ( View Tweet)
Are Emulation Trials a Fantasy?
Are these ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)?
https://t.co/x6NogGQksW https://t.co/f8o8N55tlJ
Dr. John Cush RheumNow ( View Tweet)
axSpA: Moving the needle in time to diagnosis
The journey to axial spondyloarthritis (axSpA) diagnosis is often prolonged and challenging. Understanding the factors contributing to the delays is important to improve the clinical, psychological, social and economic outcomes.… https://t.co/wnwtj8jj0q https://t.co/Pds2uxVfJV
Dr. John Cush RheumNow ( View Tweet)
Assessment and management of axSpA
Dr. Antoni Chan reports on abstract 0818, Defining BASDAI Cut-offs for Disease Activity States in Axial Spondylarthritis – Results from the EuroSpA Collaboration, and abstract 0819, The Assessment of SpondyloArthritis International Society… https://t.co/ropQJdElyb https://t.co/IVn5u2l7iP
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Are we under-monitoring in scleroderma ILD?
Dr. Janet Pope discusses abstract 0678, Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually, and abstract 0706, Single Center Prospective Cohort of… https://t.co/1y1VXGvqjp https://t.co/4ofh45cYwq
Dr. John Cush RheumNow ( View Tweet)
Hypoxia seems to exacerbate neutrophil activation by ANCA
- enhanced F-Actin polymerization
- enhanced NET formation
Could hypoxia predilection in certain tissues (kidney, lung) lead to the AAV phenotypic disease patterns?
@RheumNow #ACR24 https://t.co/KxaeMvkd2t
Links:
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Prior studies have shown that IFN is increased in non-lesional skin of SLE pts.
In this study, they found a ⬆️ expression of IFN stimulated genes (ISGs) in pts w/ a history of CLE.
No correlation w/ CLASI act & IFN scores but only few pts.
@RheumNow #ACR24 abs2678 https://t.co/cPT6yPkoCb
Links:
sheila RHEUMarampa ( View Tweet)
Prof Petri reports the ff predictors of fracture in SLE:
-older age
-Caucasian race
-female sex
⚠️ Prednisone (but not recent IM triamcinolone or IV methylpred) is a MAJOR risk factor.
When possible, avoid prednisone!
@RheumNow #ACR24 #ACRbest abs2679
@rheumarhyme https://t.co/q2NMRaYsAF
Links:
sheila RHEUMarampa ( View Tweet)
Lacaille et al. Long term harms of previous steroids in RA. CV/infection mortality increase 7% every year/use. Takes 3.5 and 10 years to return to normal after 1 and 2 years use. Never returns to normal if >2 years use @RheumNow #ACR24 Abstr#2673 #ACRbest https://t.co/qcp5mCHmeB https://t.co/keXw5Qg2ld
Links:
Richard Conway RichardPAConway ( View Tweet)
All-caps abstract text throw-down by Michelle Petri re:fractures in SLE 😆
I keep saying this; our obsesssion with vitamin d is not commensurate w/reality
It's. The. Prednisone.
#ACR24 @RheumNow Abstr#2679 #ACRBest https://t.co/13luByNvYT
Links:
Mike Putman EBRheum ( View Tweet)
What are the predictors of fracture in #SLE?
🦴Prednisone! Even at low doses ≤5mg
🦴Stroke
🦴Caucasian race
🦴Female
🦴Low BMD
Try to avoid steroid use. If they are needed, IM triamcinolone or IVMP preferable to oral GC.
Ab2679 #ACR24 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
Does CVD mortality risk change after stopping GC in RA?
➡️28078 incident GC users
➡️Incr mortality risk from CVD &infections persists post-cessation
➡️Risk never returns to pre-GC level after prolonged use
⏩Use GC at lowest dose for shortest time possible
Ab2673 #ACR24 @Rheumnow https://t.co/dtLU8obLke
Links:
Mrinalini Dey DrMiniDey ( View Tweet)
Increased risk of mortality related to negative effects of GC use persists long after stopping and never return to pre-GC levels. #GCStewardship
#ACR24 @RheumNow ABST#2673 https://t.co/5AwHDmvQGf
Jiha Lee JihaRheum ( View Tweet)
Ab2674 #ACR24
➡️Most pts starting 1st-line TNFi, who didn't achieve treatment response at 3M, also didn't achieve response from months 3-12
➡️1/4 pts achieving LDA/remission at 3M were no longer in LDA/remission at 12M
@RheumNow https://t.co/pFOo86tJTx
Mrinalini Dey DrMiniDey ( View Tweet)